Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

BioSpecifics Technologies Corp., a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX in the U.S. and Xiapex in Europe, today announced its financial results for the fourth quarter and full year ended December 31, 2015 and provided a corporate update.

14 Mar 2016

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2015.

12 Feb 2016

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

AbbVie, in cooperation with Neurocrine Biosciences, Inc., today announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo.

29 Jan 2016

High testosterone levels in women may increase uterine fibroid risk

Women who have high levels of both testosterone and estrogen in midlife may face a greater risk of developing benign tumors on the uterus called uterine fibroids than women with low levels of the hormones, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.

16 Dec 2015

Morgan brings industry-leading ceramics to HIFU transducers

Morgan Advanced Materials, widely acknowledged as a global leader in ceramics and other advanced materials, has announced that it now has the capability to design and manufacture components for use in high intensity focused ultrasound (HIFU) technologies, particularly in medical applications.

10 Dec 2015

Boston Scientific signs definitive agreement to acquire CeloNova's interventional radiology business

Boston Scientific has entered into a definitive agreement to acquire the interventional radiology portfolio of CeloNova Biosciences, a San Antonio-based developer of endovascular and interventional cardiology technologies.

10 Nov 2015

SonaCare Medical's Sonablate 450 focused ultrasound system receives FDA approval for ablation of prostate tissue

The US Food and Drug Administration has approved SonaCare Medical's Sonablate 450 focused ultrasound system for the ablation of prostate tissue. Focused ultrasound enables treatment of organ-confined prostate disease while preserving surrounding healthy tissue, without radiation or surgery.

14 Oct 2015

Researchers perform first focused ultrasound treatments in the U.S. for dyskinesia

Researchers at the University of Maryland and the University of Virginia have performed the first focused ultrasound treatments in the United States for dyskinesia associated with Parkinson's disease.

2 Sep 2015

Many reproductive-age women experience pelvic pain that goes untreated, study finds

A high proportion of reproductive-age women may be experiencing pelvic pain that goes untreated, according to a study by researchers from the National Institutes of Health and the University of Utah School of Medicine, Salt Lake City.

12 Aug 2015

XIAFLEX approved in Japan for treatment of patients with Dupuytren's contracture

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, announced that Asahi Kasei Pharma Corporation has received approval for its regulatory application to the Japanese Pharmaceutical and Medical Device Agency (PMDA) for XIAFLEX (collagenase clostridium histolyticum) for the treatment of patients with Dupuytren's contracture in Japan.

20 Jul 2015

Updated SOGC guidelines include FIBRISTAL as only approved medical treatment for uterine fibroids

The Society for Obstetrics and Gynecology of Canada has issued updated guidelines for the management of uterine fibroids (uterine leiomyomas), which now include the first and only approved medical treatment for uterine fibroids: FIBRISTAL (ulipristal acetate).

4 Jun 2015

Children's National Health System first in U.S. to treat osteoid osteoma using MR-HIFU method

Doctors from the Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System are the first in the United States to treat osteoid osteoma, a benign but painful bone tumor that commonly occurs in children and young adults, using an experimental magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) method.

28 May 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.

30 Apr 2015

OHTAC recommends MRgHIFU as possible cost-effective strategy for uterine fibroid treatment

The Ontario Health Technology Advisory Committee has recommended Magnetic Resonance-Guided High-Intensity Focused Ultrasound (MRgHIFU or MRgFUS) as a possible "cost-effective strategy" and a "safe and effective, noninvasive, uterine-preserving" option for women seeking treatment for uterine fibroids.

27 Apr 2015

Alternative treatment options for uterine fibroids

A 47-year-old African-American woman has heavy menstrual bleeding and iron-deficiency anemia. She reports the frequent need to urinate during the night and throughout the day. A colonoscopy is negative and an ultrasonography shows a modestly enlarged uterus with three uterine fibroids, noncancerous growths of the uterus.

24 Apr 2015

Study compares cost, benefits, complications of uterine-sparing treatments for fibroids

The relative cost, benefits, and complications of three minimally invasive techniques for reducing or eliminating symptomatic uterine fibroids are being compared in women who don't have cancer and want to preserve their uterus.

30 Mar 2015

VIVA physician selected as new Fellows in the Society of Interventional Radiology

Dr. John D. Statler, a board-certified, fellowship-trained Interventional Radiologist with Virginia Interventional & Vascular Associates, is one of only 23 physicians nationwide selected this year as new Fellows in the Society of Interventional Radiology.

26 Mar 2015

Laparoscopic hysterectomy with morcellation safer than abdominal procedure for treating presumed fibroid uterus

In a new study published in the American Journal of Obstetrics & Gynecology, researchers from The University of North Carolina at Chapel Hill compared the relative risks of laparoscopic hysterectomy (with morcellation) with abdominal surgery for hysterectomy in premenopausal women undergoing surgery for presumed uterine fibroids.

25 Mar 2015

BioSpecifics Technologies provides corporate update, reports Q4 and FY 2014 financial results

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the fourth quarter and full year ended December 31, 2014 and provided a corporate update.

13 Mar 2015

Study: Risk of uterine sarcoma fairly low in women following hysterectomy

Uterine sarcoma - a potentially aggressive type of cancer that forms in tissues in the uterus - was found in 0.22 % of women following a hysterectomy for benign conditions, a new large-scale study by the University of Michigan departments of Obstetrics and Gynecology, and Surgery finds.

20 Feb 2015

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

BioSpecifics reports net income of $2.7 million for fourth quarter 2015

Neurocrine Biosciences reports net loss of $29.3 million for fourth quarter 2015

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

High testosterone levels in women may increase uterine fibroid risk

Morgan brings industry-leading ceramics to HIFU transducers

Boston Scientific signs definitive agreement to acquire CeloNova's interventional radiology business

SonaCare Medical's Sonablate 450 focused ultrasound system receives FDA approval for ablation of prostate tissue

Researchers perform first focused ultrasound treatments in the U.S. for dyskinesia

Many reproductive-age women experience pelvic pain that goes untreated, study finds

XIAFLEX approved in Japan for treatment of patients with Dupuytren's contracture

Updated SOGC guidelines include FIBRISTAL as only approved medical treatment for uterine fibroids

Children's National Health System first in U.S. to treat osteoid osteoma using MR-HIFU method

Neurocrine reports net loss of $1.2 million for first quarter 2015

OHTAC recommends MRgHIFU as possible cost-effective strategy for uterine fibroid treatment

Alternative treatment options for uterine fibroids

Study compares cost, benefits, complications of uterine-sparing treatments for fibroids

VIVA physician selected as new Fellows in the Society of Interventional Radiology

Laparoscopic hysterectomy with morcellation safer than abdominal procedure for treating presumed fibroid uterus

BioSpecifics Technologies provides corporate update, reports Q4 and FY 2014 financial results

Study: Risk of uterine sarcoma fairly low in women following hysterectomy

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in